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between the two groups was used Chi Square Test. To evaluate
differences in EQ VAS was used both Paired sample T test and
a regression analysis using bootstrap estimated of standard error.
RESULTS: No statistically signiﬁcant differences were reported
in all dimensions between the two groups: mobility (P = 1.000),
self care (P = 0.064), usual activities (P = 0.213), pain/discom-
fort (P = 0.213) and anxiety/depression (P = 0.512). The ﬁgures
obtained using VAS to assess the global health status was: 72.8
(SD, ± 19.7) in patients treated with VKA and 73.9 (SD, ± 16.0)
in matched controls; this difference was not statistically signiﬁ-
cant (p = 0.708 Paired sample T); also bootstrap conﬁdent 
intervals indicated that there was no statistically signiﬁcant 
differences between the two groups. CONCLUSIONS: Even if it
is conceivable that different settings would give different results,
our study show that in patients on oral anticoagulant treatment
the overall perception of health status was not signiﬁcantly dif-
ferent from that of matched controls.
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OBJECTIVE: Wide use of disease-oriented quality of life (QoL)
measures, that are not preference based, and thus lack legitimacy
for direct use in economic evaluations, has prompted a need for
modeling to derive utilities. The QoL Assessment of Growth
Hormone Deﬁciency in Adults questionnaire (QoL-AGHDA) is
a disease-oriented measure used to assess impairment in QoL in
adults with growth hormone deﬁciency. The present study aims
to provide a model for deriving utilities directly from the QoL-
AGHDA. METHODS: The EQ-5D and the QoL-AGHDA were
mailed to a random sample (n = 2990) of the Swedish popula-
tion (response rate, 65%). The Jack knife method was used to
obtain cross-validated parameters of QoL-AGHDA-based utili-
ties. Using the EQ-5Dindex (derived from European values) as the
dependent variable, and age, gender and QoL-AGHDA score as
independent variables in repeated regression analyses, each time
omitting one tenth of the sample (the Jack-knife method) esti-
mates for the coefﬁcients for transformation of the QoL-
AGHDA into a single score (range, 0–1) were achieved. These
transformed QoL-AGHDA scores correspond to the QoL-
AGHDA-based utility. RESULTS: The transformation algorithm
was: U (QoL-AGHDA-based utilities) = [102.2 - 1.80*QoL-
AGHDA score - 0.227 * age - 1.21*Gender (men = 0; women
= 1)]/100. The mean of the weighted estimate for the total pop-
ulation (n = 1752) was 0.83 (SD, 0.09). The estimate for men (n
= 861; mean, 0.84; SD, 0.09) was higher (p < 0.001) than for
women (n = 891; mean, 0.82; SD, 0.09). CONCLUSION: The
present model could be used to derive utilities directly from the
QoL-AGHDA; however, it should be highlighted that the coefﬁ-
cients presented here come from the homogeneous Swedish pop-
ulation and thus application to other populations should be
carefully considered.
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Although the beneﬁcial effect of growth hormone replacement
on QoL in adults with GHD is well recognized, the long-term
effect of this therapy on QoL remains uncertain. OBJECTIVES:
To determine the effect of long term GH replacement on QoL in
patients compared with country-speciﬁc normative data for the
general population (GP). METHODS: QoL was measured using
Quality of Life Assessment for Growth Hormone Deﬁciency in
Adults (QoL-AGHDA) in patients and GP in Sweden and
England & Wales (E&W). QoL-AGHDA is a 25-item question-
naire that elicits yes/no responses that are used to compute a
summary score. GP data were obtained from 1682 randomly
selected individuals from Sweden and 892 from E&W. These
data were compared with KIMS (Pﬁzer International Metabolic
Database) data for 121 patients from Sweden and 77 from E&W
with 5 years of complete follow-up. Age-range was 20–79 years.
Linear regression methods were used to estimate age- and
gender-adjusted differences between patients and the GP at one-
year intervals. The signiﬁcance level was set at 5%. RESULTS:
The (adjusted to age 50) mean QoL-AGHDA score at baseline
were 8.21 and 15.2 (SEM 0.44 and 0.68) for the Swedish and
E&W patients, respectively. For the GP samples the corre-
sponding mean scores were 3.80 and 6.6 (SEM 0.12 and 0.20).
The mean difference between patient scores at baseline and GP
scores were -4.4 for Sweden and -8.6 for E&W (p < 0.0001).
However, these differences reduced markedly over the ﬁrst year
of treatment and were subsequently maintained at statistically
non-signiﬁcant differences compared to the general populations.
CONCLUSIONS: This study shows that adults with GHD who
receive long-term GH replacement beneﬁt most with respect to
QoL during the ﬁrst 12 months of therapy and that this improve-
ment was maintained at levels close to normalization in QoL
over 5 years of follow up.
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OBJECTIVES: To evaluate the impact of acromegaly on health-
related quality of life (HRQOL) in European patients treated
with Sandostatin® LAR®. The secondary objectives were to
investigate the correlation between HRQOL and subpopulations
based on exploratory variables [sociodemographic and disease-
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speciﬁc markers, e.g. growth hormone (GH) and insulin-like
growth factor (IGF-I)] and to compare the results of the 22-item
[8 physical and 14 psychological] Acromegaly Quality-of-Life
questionnaire [ACROQOL] and Short Form-36 Health Survey
[SF-36] in this population. Some of data collected will support
also the ongoing validation of ACROQOL questionnaire.
METHODS: This is the largest European multinational, open,
non-comparative, single evaluation, observational trial evaluat-
ing the HRQOL of patients with acromegaly treated with San-
dostatin® LAR®. This preliminary analysis presents interim
results from 208 Italian and 71 Spanish patients. Recruitment is
ongoing in England, France, Germany, Greece, Portugal, and
Turkey. A total of more than 500 patients are expected. GH and
IGF-I levels were measured within two months of completion 
of the questionnaires and sociodemographic data were also
recorded. Multivariate analyses were used to explore relation-
ship between HRQOL score and clinical and sociodemographic
variables. RESULTS: From this preliminary analysis, there was
no apparent relationship between HRQOL and sociodemo-
graphic variables; and no correlation with levels of GH or IGF-
I. There was a marked correlation between ACROQOL and
physical component score of SF-36, but less signiﬁcant correla-
tion between ACROQOL and mental component score. The
overall impact of acromegaly on HRQOL in patients treated
with Sandostatin® LAR® has not yet been analysed. CON-
CLUSIONS: ACROQOL may be a more descriptive measure of
HRQOL in the acromegaly population than the SF-36. In terms
of the SF-36, there was a superior correlation between the phys-
ical function component and ACROQOL than with the mental
component score, suggesting that the ACROQOL is more sensi-
tive to the psychological impact of the disease.
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OBJECTIVES: To investigate whether long-term GH replace-
ment in GH deﬁcient adults results in improvements in PRO and
HCU in comparison with Dutch population data. METHODS:
Analyses were performed using data from KIMS (Pﬁzer Interna-
tional Metabolic Database). Data were available for 164 Dutch
patients (78 men) for the ﬁrst year of treatment, whereas 2 and
3-year follow-up data were available for 107 and 62 patients
respectively. Quality of life (QoL) was assessed using the Not-
tingham Health Proﬁle (NHP) and disease-speciﬁc QoL-AGHDA
questionnaire. HCU data were obtained with the Patient Life 
Situation Form (PLSF). Statistical analyses were performed with
repeated measurements technique (all values presented as mean
± SEM or mean (95% CI). Normative data for the QoL-AGHDA
questionnaire are currently being collected and will be compared
with patient data. RESULTS: Both QoL measures showed a sig-
niﬁcant sustained improvement over the 3-year treatment period
(from 7.5 ± 0.55 to 5.0 ± 0.59 for NHP, from 10 ± 0.5 to 6.8 ±
0.7 for AGHDA). Data collected with the PLSF showed a sus-
tained subjective improvement in personal well-being for more
than two-third of patients. There was a signiﬁcant decrease from
the previous years in the number of visits to the doctor (from
7.1 (5.7–8.8) to 2.7 (1.7–4.3)), days in hospital (from 5.1
(3.0–8.6) to 1.7 (0.3–8.6)) and days of sick leave (from 39
(0–120) to 1.9 (0–10)) during GH therapy. These data in com-
parison with the average number of visits to the doctor in
2004–5.3 (Source, CBS, 2005), the average number of hospital
days in 2003–4.6 days (Source, Prismant, 2005) and average
number of sick days in 2003 for the Dutch working population—
14.7 (Source, CBS, 2005) showed normalization of HCU CON-
CLUSION: Data obtained conﬁrm that GH replacement therapy
results in a sustained long-term improvement in PRO and nor-
malization of HCU in The Netherlands.
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OBJECTIVES: To evaluate the timing and degree of symptom
relief with rabeprazole in a real life setting of patients with
gastro-oesophageal reﬂux disease (GERD). METHODS: A
prospective, multi-centre, observational study was conducted in
which Canadian general practitioners (n = 115) prescribed
rabeprazole to adults with GERD. Subjects had to be newly diag-
nosed or demonstrate insufﬁcient control on their current PPI,
H2-antagonist and/or antacid and not have used rabeprazole
previously. At the baseline ofﬁce visit (Day 0), physicians col-
lected demographic and clinical history data. Subjects were 
prescribed rabeprazole (2 ¥ 10mg daily) and sent home with a
seven-day diary to record symptom severity and symptom
control. Subjects also completed a Global Symptom Rating on
Day 7 with improvement deﬁned as equal to as or greater than
1 point change in severity rating. RESULTS: Of the 312 subjects
who reported taking rabeprazole on Day 0, more than half were
over 50 years of age and 56% female. The number of subjects
reporting baseline Daytime Heartburn (D-HB), baseline Night-
time Heartburn (N-HB), and Regurgitation (R) were 245, 230
and 194 respectively. 63% of D-HB, 73% of N-HB and 72% of
R reported improvement within the ﬁrst 2 days of therapy. Of
the subjects experiencing improvement during the ﬁrst two days
of therapy, 83% of D-HB, 83% of N-HB and 82% of R main-
tained or further improved symptoms to the end of the study.
Overall, the majority of patients (76%) indicated marked (56%)
or moderate (20%) improvement for the onetime Global
Symptom Rating score on Day 7. CONCLUSIONS: Rabeprazole
demonstrated a high level of effectiveness within the ﬁrst two
days of therapy, which was maintained in subjects with a pro-
longed history of GERD, including those with prior PPI treat-
ment. The results of this real world study provided valuable
information on the true efﬁcacy of rabeprazole.
PGI2
COST EFFECTIVENESS AND BUDGET IMPACT OF
LAMIVUDINE ANTIVIRAL TREATMENT FOR CHRONIC
HEPATITIS TYPE B PATIENTS IN TAIWAN
Shau WY1, Tsai IC2, Scuffham PA3, Dziekan KX4
1GlaxoSmithKline, Singapore, Singapore; 2GlaxoSmithKline,Taipei,
Taiwan; 3University of Queensland, Brisbane, Queensland, Australia;
4GlaxoSmithKline, Greenford, Middlesex, UK
OBJECTIVES: To evaluate cost-effectiveness and budget impact
of short and long-term lamivudine antiviral treatment for
chronic hepatitis type B (CHB) in Taiwan. METHODS: A
